Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications

Chimeric Antigen Receptor T (CAR-T) cell therapy has dramatically changed prognosis and treatment of relapsed and refractory hematologic malignancies. Currently the 6 FDA approved products target various surface antigens. While CAR-T therapy achieves good response, life-threatening toxicities have b...

Descripción completa

Detalles Bibliográficos
Autores principales: Mucha, Simon R., Rajendram, Prabalini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217595/
https://www.ncbi.nlm.nih.gov/pubmed/37232836
http://dx.doi.org/10.3390/curroncol30050378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217595/
https://www.ncbi.nlm.nih.gov/pubmed/37232836
http://dx.doi.org/10.3390/curroncol30050378

Ejemplares similares